Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study

Nan Haw Chow, Ping I. Hsu, Xi Zhang Lin, Hsiao Bai Yang, Shih Huang Chan, Kuo Sheng Cheng, Shih Ming Huang, Ih Jen Su

研究成果: Article

107 引文 (Scopus)

摘要

Angiogenesis is of vital importance during the development and progression of solid tumors. To examine the role of vascular endothelial growth factor (VEGF) in hepatocarcinogenesis, we evaluated the expression of peptide in normal human liver (n = 6) and in 36 cases of hepatocellular carcinoma (HCC). Immunoreactivity for VEGF was present in the extracellular matrix of the portal tracts in the normal and nontumor part of liver, but not in hepatocytes and bile duct epithelium. For HCC, variable amounts of VEGF were expressed in 13 cases (36.1%) of tumor cells. Using a logistic regression model, expression of VEGF was significantly associated with a higher proliferative index (P = .01) and sonographic portal vein thrombosis (P = .05). However, VEGF expression did not correlate with a biochemical liver profile, alpha-fetoprotein levels, histological grading, gender, or clinical stage of cirrhosis (p > 0.1, respectively). Log-rank test showed that evaluation of VEGF did not provide more prognostic information(P > .5) than that from tumor volume and portal vein thrombosis (P < .01, respectively). In addition, VEGF was always present in the fibrovascular stroma or pericellular matrix of HCC, although no strong relationship was observed with the expression of VEGF in tumor cells (P > .5). Our data suggested that expression of VEGF may characterize a progression toward higher proliferation in hepatocarcinogenesis in vivo. The relevance of VEGF existing in the extracellular matrix of the normal liver and HCC remains to be clarified.

原文English
頁(從 - 到)698-703
頁數6
期刊Human Pathology
28
發行號6
DOIs
出版狀態Published - 1997 一月 1

指紋

Vascular Endothelial Growth Factor A
Hepatocellular Carcinoma
Liver
Portal Vein
Extracellular Matrix
Thrombosis
Logistic Models
alpha-Fetoproteins
Bile Ducts
Tumor Burden
Hepatocytes
Neoplasms
Fibrosis
Epithelium
Peptides

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

引用此文

@article{66f3a9e079f34febb8e4547a11ddde68,
title = "Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study",
abstract = "Angiogenesis is of vital importance during the development and progression of solid tumors. To examine the role of vascular endothelial growth factor (VEGF) in hepatocarcinogenesis, we evaluated the expression of peptide in normal human liver (n = 6) and in 36 cases of hepatocellular carcinoma (HCC). Immunoreactivity for VEGF was present in the extracellular matrix of the portal tracts in the normal and nontumor part of liver, but not in hepatocytes and bile duct epithelium. For HCC, variable amounts of VEGF were expressed in 13 cases (36.1{\%}) of tumor cells. Using a logistic regression model, expression of VEGF was significantly associated with a higher proliferative index (P = .01) and sonographic portal vein thrombosis (P = .05). However, VEGF expression did not correlate with a biochemical liver profile, alpha-fetoprotein levels, histological grading, gender, or clinical stage of cirrhosis (p > 0.1, respectively). Log-rank test showed that evaluation of VEGF did not provide more prognostic information(P > .5) than that from tumor volume and portal vein thrombosis (P < .01, respectively). In addition, VEGF was always present in the fibrovascular stroma or pericellular matrix of HCC, although no strong relationship was observed with the expression of VEGF in tumor cells (P > .5). Our data suggested that expression of VEGF may characterize a progression toward higher proliferation in hepatocarcinogenesis in vivo. The relevance of VEGF existing in the extracellular matrix of the normal liver and HCC remains to be clarified.",
author = "Chow, {Nan Haw} and Hsu, {Ping I.} and Lin, {Xi Zhang} and Yang, {Hsiao Bai} and Chan, {Shih Huang} and Cheng, {Kuo Sheng} and Huang, {Shih Ming} and Su, {Ih Jen}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0046-8177(97)90179-9",
language = "English",
volume = "28",
pages = "698--703",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma

T2 - An immunohistochemical study

AU - Chow, Nan Haw

AU - Hsu, Ping I.

AU - Lin, Xi Zhang

AU - Yang, Hsiao Bai

AU - Chan, Shih Huang

AU - Cheng, Kuo Sheng

AU - Huang, Shih Ming

AU - Su, Ih Jen

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Angiogenesis is of vital importance during the development and progression of solid tumors. To examine the role of vascular endothelial growth factor (VEGF) in hepatocarcinogenesis, we evaluated the expression of peptide in normal human liver (n = 6) and in 36 cases of hepatocellular carcinoma (HCC). Immunoreactivity for VEGF was present in the extracellular matrix of the portal tracts in the normal and nontumor part of liver, but not in hepatocytes and bile duct epithelium. For HCC, variable amounts of VEGF were expressed in 13 cases (36.1%) of tumor cells. Using a logistic regression model, expression of VEGF was significantly associated with a higher proliferative index (P = .01) and sonographic portal vein thrombosis (P = .05). However, VEGF expression did not correlate with a biochemical liver profile, alpha-fetoprotein levels, histological grading, gender, or clinical stage of cirrhosis (p > 0.1, respectively). Log-rank test showed that evaluation of VEGF did not provide more prognostic information(P > .5) than that from tumor volume and portal vein thrombosis (P < .01, respectively). In addition, VEGF was always present in the fibrovascular stroma or pericellular matrix of HCC, although no strong relationship was observed with the expression of VEGF in tumor cells (P > .5). Our data suggested that expression of VEGF may characterize a progression toward higher proliferation in hepatocarcinogenesis in vivo. The relevance of VEGF existing in the extracellular matrix of the normal liver and HCC remains to be clarified.

AB - Angiogenesis is of vital importance during the development and progression of solid tumors. To examine the role of vascular endothelial growth factor (VEGF) in hepatocarcinogenesis, we evaluated the expression of peptide in normal human liver (n = 6) and in 36 cases of hepatocellular carcinoma (HCC). Immunoreactivity for VEGF was present in the extracellular matrix of the portal tracts in the normal and nontumor part of liver, but not in hepatocytes and bile duct epithelium. For HCC, variable amounts of VEGF were expressed in 13 cases (36.1%) of tumor cells. Using a logistic regression model, expression of VEGF was significantly associated with a higher proliferative index (P = .01) and sonographic portal vein thrombosis (P = .05). However, VEGF expression did not correlate with a biochemical liver profile, alpha-fetoprotein levels, histological grading, gender, or clinical stage of cirrhosis (p > 0.1, respectively). Log-rank test showed that evaluation of VEGF did not provide more prognostic information(P > .5) than that from tumor volume and portal vein thrombosis (P < .01, respectively). In addition, VEGF was always present in the fibrovascular stroma or pericellular matrix of HCC, although no strong relationship was observed with the expression of VEGF in tumor cells (P > .5). Our data suggested that expression of VEGF may characterize a progression toward higher proliferation in hepatocarcinogenesis in vivo. The relevance of VEGF existing in the extracellular matrix of the normal liver and HCC remains to be clarified.

UR - http://www.scopus.com/inward/record.url?scp=0030908887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030908887&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(97)90179-9

DO - 10.1016/S0046-8177(97)90179-9

M3 - Article

C2 - 9191004

AN - SCOPUS:0030908887

VL - 28

SP - 698

EP - 703

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -